DANVILLE, Calif., May 17, 2017 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of the FreespiraŽ
Authorized by a licensed healthcare provider, Freespira is both easy to use and effective. After a single training session, the patient performs two 17-minute breathing sessions per day at home over a four-week period. A recently published multi-center clinical trial of patients utilizing the Freespira protocol demonstrated that 71% of patients eliminated panic attacks immediately after treatment, and 79% of patients were panic attack free 12 months post-treatment.
Debra Reisenthel, PAHS President and CEO, commented, "Our company is committed to developing innovative, evidence-based treatments for behavioral health conditions. We are excited to be partnering with leading clinicians to perform important new research, which includes studying the use of Freespira in patients with PTSD as well as treating significant anxiety and panic in adolescents."
About Panic AttacksPanic attacks affect an estimated 27 million in the U.S., impacting their lives in profoundly negative ways, including overall quality of life and productivity. Furthermore, panic attacks are often misinterpreted as a serious medical event such as a heart attack, which leads to excess emergency room visits, tests, medication use, and doctor visits. Given the five-fold increase in annual use of healthcare resources by these patients, fewer panic attacks are expected to lead to reduced medical utilization and costs.
About FreespiraFreespira is an FDA-cleared, non-invasive, drug-free, four-week at-home treatment for panic attacks and panic symptoms. Treatment is authorized and completed under the supervision of a licensed healthcare provider. Freespira is clinically proven to reduce or eliminate panic attacks and other symptoms of panic disorder, a mental health condition in which debilitating anxiety leads to life-altering avoidance behaviors. Many individuals with panic chronically hyperventilate, even when not experiencing a panic attack. This abnormal breathing pattern has been shown to exacerbate attacks. Freespira works by training the patient to stabilize respiration rate and exhaled carbon dioxide levels, which reduces or eliminates the chronic hyperventilation. A recent multi-center clinical trial demonstrated that at 12 months post-treatment, 79% of treated patients were free of panic attacks and 82% had significant symptom reduction.
About Palo Alto Health Sciences, Inc.Palo Alto Health Sciences, Inc. is a privately held Silicon Valley digital therapeutic company at the forefront of revolutionizing behavioral healthcare with evidence-based, non-invasive, drug-free solutions. Their first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic. In the United States, over 6.7 million adults annually suffer from panic disorder; panic attacks affect a total of 27 million adults in the U.S. every year and are a common component of other anxiety disorders.
Freespira is commercially available throughout the U.S. and is currently being evaluated by Anthem and Highmark Health in regional Quality Improvement Programs to assess Freespira's impact in reducing the elevated medical costs of treating patients with panic disorder. Separate clinical studies are underway to treat adolescents, and to treat veterans with PTSD. To learn more, visit http://www.freespira.com or contact email@example.com.
MEDIA CONTACTMichele Kong(800) firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/freespira-clinical-data-to-be-presented-at-three-upcoming-conferences-300459329.html
SOURCE Palo Alto Health Sciences
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All